Rohto Pharmaceutical Co.,Ltd.
Notice Regarding Partial Correction of the Medium- to Long-Term Growth Strategy 2026
Partial corrections were made to the Medium- to Long-Term Growth Strategy 2026 as a rolling update. Financial forecasts were revised to present outlooks toward fiscal year 2031, amending the previous targets for fiscal year 2030. Dividend payout ratio expression was changed to an outlook.
Key Figures
- Fiscal year 2031 Net sales: 4,640 hundred million yen
- Fiscal year 2031 Operating income: 598 hundred million yen
- Fiscal year 2031 Operating margin: 12.9%
AI要約
Summary of Corrections
Rohto Pharmaceutical Co.,Ltd. announced corrections to parts of the Medium- to Long-Term Growth Strategy 2026, released on October 2, 2026, due to errors. The corrections, prepared on a rolling basis, primarily include revisions to the fiscal year 2031 financial forecast, upward adjustments to the prior fiscal year 2030 forecast, and corrections to the expression of the dividend payout ratio.
Impact and Outlook
As a result of these corrections, a new financial forecast for fiscal year 2031 is presented, with raised targets for net sales and operating income, and a clarified outlook for the dividend payout ratio. The company intends to continue its policy of flexible forecasting and outlook adjustments through rolling updates.
Rohto Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
